Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Crohn's Disease

NCT02038920 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02038920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02038920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Crohn's Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2014
Completion date
May 21, 2019
Enrollment
157 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease